NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Wuxi Pharma Tech
»13/05/2010 [Company watch]
WuXi PharmaTech Reports Strong Q1 Revenues

WuXi PharmaTech reported Q1 revenues rose 36% to $80.6 million, helped by a very large increase in its contract manufacturing division, which grew 433% to $13.6 million. In WuXi’s core Lab Services business, revenues were up 18%. GAAP net income climbed 32% to $15.5 million or 21 cents per share.

 
WuXi PharmaTech reported Q1 revenues rose 36% to $80.6 million, helped by a very large increase in its contract manufacturing division, which grew 433% to $13.6 million. In WuXi’s core Lab Services business, revenues were up 18%. GAAP net income climbed 32% to $15.5 million or 21 cents per share. The company showed some optimism about the rest of the year. It now expects full-year 2010 revenues to be at the high end of its previous $310-$320 million forecast, about an 18-19% growth rate. China-based lab services will increase about 15% while revenues from manufacturing will jump at least 70%. WuXi also pointed out that its laboratory business was higher because of increased offerings such as DMPK/ADME, biology, process research, formulation and analytical services. It said manufacturing was strong because of delivery of a single large project and increasing demand. On the other hand, startup costs of its Suzhou toxicology facility had a negative effect on earnings. In late April, WuXi agreed to be acquired by Charles River Labs (NYSE: CRL) for $1.6 billion. The two companies expect the transaction to close in Q4 of 2010.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.